Overview
PCSA market data
Price History
PCSA price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$10.36 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.28 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -2,981.3% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.67 – $14.24 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $7M · P/B 1.17 · P/S 86.20.
Company News
8-K filing — Processa Pharmaceuticals, Inc. (PCSA)SEC EDGAR · Aug 4, 2026, 9:25 PM
Crude Oil Surges 7%; General Dynamics Posts Upbeat EarningsBenzinga · Jul 29, 2026, 4:01 PM
Dow Tumbles 400 Points; Procter & Gamble Shares Fall After Q4 ResultsBenzinga · Jul 29, 2026, 1:45 PM
Processa Pharmaceuticals shares are trading lower after the company announced a $200 million private placement and acquisition of Vidya Therapeutics BTK Inhibitor VT-7208.Benzinga · Jul 29, 2026, 12:51 PM
Processa Announces $200M Private Placement And Acquisition Of Vidya Therapeutics BTK Inhibitor VT-7208; Existing Shareholders To Own About 0.9% Fully DilutedBenzinga · Jul 29, 2026, 11:30 AM